No tax




Security policy (edit with Customer reassurance module)


Delivery policy (edit with Customer reassurance module)


Return policy (edit with Customer reassurance module)

Active ingredient and dosage form

1 ml of the solution contains recombinant alpha-2 human Interferon at least 10,000 IU;
10 ml in dropper bottles, in a box one bottle.

Mechanism of action

Antiviral, immunomodulatory, anti-inflammatory and antimicrobial.
Grippferon is a broad-spectrum drug (rhino-, crown-adenoviruses, influenza, parainfluenza, etc.). When the intranasal route of administration provides prolonged contact with the mucous membrane of the nasal cavity, acting on the site of the initial introduction and reproduction of respiratory viruses. The activity of 1 bottle of Grippferon is equal to the activity of 100 ampoules of human leukocyte interferon.
To Grippferon does not develop addiction and resistance. The drug, as a rule, does not require additional symptomatic treatment (aspirin, Panadol, sulfonamides, vasoconstrictor nasal drops). Carefully selected composition, due to the additional absorbent and drying effect, allows to enhance the therapeutic effect of interferon itself.
From the first hours of taking the drug, there is a withdrawal of the main symptoms of the disease (runny nose, fever, headache, oropharyngeal hyperemia, etc.). Using Grippferon at the first signs of the disease leads to its interruption.On average, the duration of the disease is reduced by 30-50%.
The use of Grippferon several times reduces the risk of complications: bronchitis, sinusitis, pneumonia, etc. (up to 3.2 times). The use of Grippferon for individual emergency prophylaxis gives a guarantee of protection against the disease up to 96%. Using the immunofluorescence method, it was shown that the introduction of Grippferon helped reduce the release of viral antigens found in the nasal passages of patients within 2 days after the start of treatment. Accordingly, patients cease to be infectious, the chain of infection is interrupted, which is important for organized groups. This was confirmed when using the drug for prophylactic purposes (during the epidemic in organized groups, the incidence decreased 2.5-3.5 times). The drug has been successfully used for the prevention of nosocomial respiratory viral infections, prevents the occurrence of outbreaks of SARS in hospitals.

Prevention and treatment of influenza and ARVI in children from birth and adults, including pregnant women.


Individual intolerance to interferon drugs and components that make up the drug; severe forms of allergic diseases.

Pregnancy and Breastfeeding

Permitted for use during the entire period of pregnancy in accordance with the age dosage.

Dosage and administration

At the first signs of the disease, instilled into the nose for 5 days:
children under 1 year - 1 drop in each nasal passage 5 times a day (single dose of 1,000 IU, daily dose of 5,000 IU);
children from 1 to 3 years - 2 drops in each nasal passage 3-4 times a day (single dose of 2000 ME, daily - 6000 - 8000 ME);
children from 3 to 14 years - 2 drops in each nasal passage 4-5 times a day (single dose of 2000 ME, daily dose of 8000-10000 ME);
for adults - 3 drops in each nasal passage 5-6 times a day (single dose 3 000 ME, daily dose 15 000 - 18 000 ME).

For the purpose of prophylaxis (ARVI and flu): when in contact with a patient and / or during hypothermia, the drug is instilled at an age dosage 2 times a day for 5-7 days. If necessary, preventive courses repeat; with a seasonal increase in the incidence of the drug buried in the age dosage in the morning after 1-2 days.

After each instillation, it is recommended to massage the wings of the nose with your fingers for a few minutes to evenly distribute the drug in the nasal cavity.

The simultaneous use of intranasal vasoconstrictor drugs due to the strengthening of the drying effect on the nasal mucosa is not recommended.

Store at a temperature of 2 to 8 ° C in a dry, dark place and out of reach of children.


43 Items